Day: June 1, 2020

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the enrollment of the first patient in its Phase 1b/2a clinical trial of HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men.This blinded, randomized, placebo controlled, single site study will enroll 36 subjects with male pattern hair loss using a 2:1 randomization HST 001 to placebo. It is designed to assess the safety and tolerability of HST 001, as well as indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography.“The initiation of this clinical trial is a critical milestone for Histogen following...

Tarrytown, NY, June 01, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Nightfood, Inc. (OTCQB: NGTF), the better-for-you snack company targeting the $50 billion consumers spend on nighttime snacks, is pleased to announce the busiest e-commerce day in Company history on Thursday, May 28, 2020 on the strength of a re-airing of a Nightfood appearance on The Rachael Ray Show, originally aired on February 24, 2020.Online sales after the re-airing were over 35% higher than after the original air date in February, which was previously the busiest e-commerce day for Nightfood.  Management attributes this increase to more people being at home as a result of ongoing stay-at-home orders in many parts of the country, along with more people being concerned about health and sleep quality as a result of the COVID-19 pandemic.“We were already...

CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will provide a corporate update at the Jefferies 2020 Virtual Healthcare Conference at 9:00 a.m. ET on Thursday, June 4, 2020.A webcast of the presentation may be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab.  A replay of the presentation will be archived on the website for 90 days following the conclusion of the event.About...

Atlanta, June 01, 2020 (GLOBE NEWSWIRE) — Acuity Brands, Inc. (NYSE: AYI) today announced it has entered into a strategic alliance agreement with Ushio America, Inc.(Ushio). Ushio has agreed to supply Acuity Brands with its Care222® UV disinfection module, which uses filtered excimer lamps to generate 222nm far-UVC light capable of inactivating viruses and bacteria on indoor surfaces.  Acuity Brands plans to incorporate these lamps in a range of its products, including its ceiling and wall-mounted lighting fixtures that can operate in occupied or unoccupied spaces, to reduce pathogens. The agreement is exclusive to Acuity Brands for general illumination uses throughout North America.  Acuity Brands also has non-exclusive rights to use the Care222 disinfection module worldwide (except Asia) for lighting and other uses.When incorporated...

Savosolar PlcCompany Announcement                   1 June 2020 at 2.15 p.m. (CEST)NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.The subscription period for Savosolar’s rights issue begins today; the company invites investors to virtual investor meetingsThe subscription period for Savosolar Oyj’s (“Savosolar” or “the Company”) rights issue (“the Offering”) begins today 1 June 2020 and will end on 15 June 2020 in Sweden and on 17 June 2020 in Finland. In connection with the Offering the Company is inviting potential investors for virtual investor meetings organised on 3 June 2020 in both Finnish and English.On 25 May 2020, the Company...

Savosolar OyjYhtiötiedote                            1.6.2020 klo 14.15 (CEST)EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI KOKONAISUUDESSAAN TAI OSITTAIN EIKÄ SUORAAN TAI VÄLILLISESTI YHDYSVALLOISSA, AUSTRALIASSA, KANADASSA, HONGKONGISSA, JAPANISSA, UUDESSA-SEELANNISSA TAI ETELÄ-AFRIKASSA TAI MISSÄÄN MUUSSA VALTIOSSA, JOSSA LEVITTÄMINEN TAI JULKAISEMINEN OLISI LAINVASTAISTA.Savosolarin merkintäoikeusannin merkintäaika alkaa tänään; yhtiö kutsuu sijoittajia virtuaalisiin sijoittajatapaamisiinSavosolarin (”Savosolar” tai ”Yhtiö”) merkintäoikeusannin (”Osakeanti”) merkintäaika alkaa tänään 1.6.2020 ja päättyy 15.6.2020 Ruotsissa ja 17.6.2020 Suomessa. Osakeannin yhteydessä Yhtiö kutsuu potentiaalisia sijoittajia suomen- ja englanninkielisiin virtuaalitapaamisiin, jotka järjestetään 3.6.2020.Yhtiö julkaisi 25.5.2020 Osakeannin yhteydessä esitteen....

Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020Norwood, MA, June 01, 2020 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, announced baseline patient demographics and disease characteristics in its Phase 2b study of lenabasum in cystic fibrosis. The information was published in an electronic supplement of the Journal of Cystic Fibrosis in connection with the 43rd European Cystic Fibrosis Conference. Topline results from the Phase 2b cystic fibrosis study are on track for the summer of 2020.Abstract Title: Patient demographics and baseline...

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2020 Jefferies Virtual Healthcare Conference on Thursday, June 4th, at 4:00 pm EDT.To access a live webcast of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.About TRACONTRACON develops targeted therapies for cancer utilizing a capital...

CORAL GABLES, Fla., June 01, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the Company will be presenting at the Jefferies Virtual Healthcare Conference being held June 2-4, 2020. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D. Chief Scientific Officer /COO, will be hosting one-on-one meetings with investors via organized conference calls and will be presenting on Thursday, June 4 at 8:30 a.m. E.T.The presentation will be available on the Investor page of the company’s website at www.catalystpharma.com.About Catalyst PharmaceuticalsCatalyst Pharmaceuticals...

REHOVOT, Israel and WILMINGTON, Del., June 01, 2020 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced Ayala management will present at two upcoming investor conferences:Jefferies Virtual Global Healthcare Conference: Wednesday, June 3, 2020 at 10:30 am ET.Raymond James 2020 Human Healthcare Innovation Conference: Thursday, June 18, 2020 at 8:20 am ET.A live webcast of each presentation may be accessed by visiting the Investors and News section of Ayala’s website at www.ir.ayalapharma.com. An archived replay of each webcast will be available on the website for 90 days following the presentations.About...